Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade.
chemotherapy
glioblastoma
overall survival
radiotherapy
rapid early progression
real-world evidence
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
03
2020
accepted:
28
04
2020
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
29
7
2020
Statut:
epublish
Résumé
The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003-12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (
Identifiants
pubmed: 32719739
doi: 10.3389/fonc.2020.00840
pmc: PMC7348058
doi:
Types de publication
Journal Article
Langues
eng
Pagination
840Informations de copyright
Copyright © 2020 Lakomy, Kazda, Selingerova, Poprach, Pospisil, Belanova, Fadrus, Vybihal, Smrcka, Jancalek, Hynkova, Muckova, Hendrych, Sana, Slaby and Slampa.
Références
Lancet Oncol. 2008 Jan;9(1):29-38
pubmed: 18082451
Radiother Oncol. 2016 Jan;118(1):35-42
pubmed: 26777122
Klin Onkol. 2011;24(2):112-20
pubmed: 21644366
Cancers (Basel). 2019 Feb 02;11(2):
pubmed: 30717372
Int J Mol Sci. 2014 Jul 03;15(7):11832-46
pubmed: 24995696
J Neurooncol. 2017 Apr;132(2):249-254
pubmed: 28101701
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
J Clin Oncol. 2017 Jan 20;35(3):361-369
pubmed: 27893327
Neuro Oncol. 2016 Mar;18(3):303-5
pubmed: 26917587
Am J Clin Oncol. 2019 May;42(5):481-486
pubmed: 30973372
Neuro Oncol. 2017 Aug 1;19(8):1119-1126
pubmed: 28371907
J Clin Oncol. 2008 May 1;26(13):2192-7
pubmed: 18445844
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Neuro Oncol. 2008 Jun;10(3):361-7
pubmed: 18401015
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Am J Clin Oncol. 2012 Jun;35(3):284-9
pubmed: 21399487
Neuroimage Clin. 2016 Feb 26;11:316-321
pubmed: 27298760
J Neurooncol. 2017 Aug;134(1):169-175
pubmed: 28547592
J Neurooncol. 2017 Aug;134(1):213-219
pubmed: 28567589
Eur J Cancer. 2015 Mar;51(4):522-32
pubmed: 25616647
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
CNS Oncol. 2019 Mar 1;8(1):CNS28
pubmed: 30806082
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
J Neurooncol. 2010 May;98(1):93-9
pubmed: 19960228
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Neuro Oncol. 2017 Jul 1;19(7):965-975
pubmed: 28039367
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep 13;:
pubmed: 31544900
J Clin Oncol. 2008 Sep 1;26(25):4189-99
pubmed: 18757334
Radiol Oncol. 2018 Jun 6;52(2):121-128
pubmed: 30018514
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Sci. 2011 Dec;102(12):2186-90
pubmed: 21895872
Mayo Clin Proc. 2017 Jun;92(6):995-1004
pubmed: 28578786
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318